At this point, efforts have been focused on the triple-negative (TN) BC subtype, as it shows higher levels of tumor infiltrating lymphocytes (TILs) and programmed death-ligand 1 (PD-L1) in its tumor microenvironment [4–6], which are currently suggested as the best predictive immune biomarkers to guide immunotherapy in BC. Here, CD274 is linked to neoplasm.